2020-08-25T17:33:21-05:00 2019-12-31 951777440 GREEN HASSON & JANKS LLP 10990 WILSHIRE BLVD 16TH FLOOR LOS ANGELES CA 900243929 990 2019-01-01 261636099 MELANOMA RESEARCH ALLIANCE FOUNDATION MELA 2023368935 730 15TH ST NW 4TH FLOOR WASHINGTON DC 20005 MICHAEL KAPLAN PRESIDENT/CEO 2023368935 2020-08-25 1 LIZBETH G NEVAREZ P01399868 3108731600 67.188.37.51 2020-08-25 12:19:54 PD P DA39A3EE5E6B4B0D3255BFEF95601890AFD80709 2587BE1C25B3BFA02F446B0EB6A11A2590CF84A1 2019 2020-11-19 02:30:22Z X MICHAEL KAPLAN 730 15TH ST NW 4TH FLOOR WASHINGTON DC 20005 23723930 0 X WWW.CUREMELANOMA.ORG X 2007 DE TO ACCELERATE SCIENTIFIC DISCOVERY TO ELIMINATE SUFFERING AND DEATH DUE TO MELANOMA 23 22 16 50 0 0 5541600 22337473 0 0 367582 343373 -64999 -168073 5844183 22512773 13770735 10156975 0 0 1588652 1580118 0 0 489448 1264467 1293934 16623854 13031027 -10779671 9481746 37272765 43192719 17748650 12810233 19524115 30382486 X TO END SUFFERING AND DEATH DUE TO MELANOMA BY COLLABORATING WITH ALL STAKEHOLDERS TO ACCELERATE POWERFUL RESEARCH, ADVANCE CURES FOR ALL PATIENTS, AND PREVENT MORE MELANOMAS. 1 0 11684054 10156975 THE MELANOMA RESEARCH ALLIANCE FOUNDATION ("MRA") SUPPORTS AMBITIOUS AND INNOVATIVE PROJECTS, SELECTED THROUGH A PEER-REVIEW PANEL AND INITIATED BY INDIVIDUAL SCIENTISTS AND SCIENCE RESEARCH TEAMS, TO PREVENT, DETECT AND TREAT MELANOMA. MRA CONVENES A WORLD CLASS, CROSS-DISCIPLINARY GROUP OF EXPERT RESEARCHERS POSSESSING CLINICAL AND SCIENTIFIC EXPERTISE TO DEVELOP A RESEARCH AGENDA THAT WILL PROVIDE INNOVATIVE SOLUTIONS TO CRITICAL RESEARCH ISSUES LEADING TO MORE EFFECTIVE PREVENTION, EARLIER DETECTION AND BETTER TREATMENTS FOR MELANOMA. MRA MAKES GRANTS TO DOMESTIC AND FOREIGN RESEARCH UNIVERSITIES, MEDICAL SCHOOLS, AND NONPROFIT MEDICAL RESEARCH ORGANIZATIONS DIRECTLY INVOLVED IN DETERMINING THE CAUSES AND CURES OF MELANOMA ON THE CONDITION THAT SUCH RESEARCH BE MADE AVAILABLE TO THE SCIENTIFIC COMMUNITY. 396424 THE MRA OPERATES A PATIENT ENGAGEMENT PROGRAM THAT SUPPORTS INCREASED AWARENESS OF MELANOMA IN GENERAL, AND OF PREVENTION, DETECTION AND TREATMENT OPTIONS SPECIFICALLY. THE PATIENT ENGAGEMENT PROGRAM ALSO PROVIDES EDUCATION ABOUT AND PROMOTION OF CLINICAL TRIALS. THE PATIENT ENGAGEMENT PROGRAM INCLUDES DEVELOPMENT AND DISTRIBUTION OF EDUCATIONAL MATERIALS, THE PROVISION OF EDUCATIONAL FORUMS, A CLINICAL TRIAL NAVIGATOR FOR PATIENTS AND AN ON-LINE PATIENT COMMUNITY. 12080478 1 1 0 1 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 1 1 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 1 1 0 0 0 1 0 0 0 1 X 8 0 1 16 1 0 0 0 0 0 1 1 1 1 0 0 0 0 0 X 23 22 1 0 0 0 0 0 0 1 0 0 0 1 1 1 1 1 1 1 1 0 AL AK AR CA CO CT DC FL GA HI IL KS KY ME MD MA MI MN NV NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI X X MICHAEL KAPLAN 2023368939 730 15TH ST NW 4TH FLOOR WASHINGTON DC 20005 MICHAEL KLOWDEN DIRECTOR 0.30 40.00 X 0 747272 40231 JOHN HUNTER TREASURER 1.00 40.00 X 0 379511 51056 MICHAEL KAPLAN PRESIDENT & CEO 50.00 0.00 X 344030 0 26764 MARC HURLBERT CHIEF SCIENCE OFFICER 50.00 0.00 X 298529 0 23064 KRISTEN MUELLER SCIENTIFIC PROGRAM DIRECTOR 40.00 0.00 X 151702 0 6699 CODY BARNETT DIRECTOR OF COMMUNICATIONS 40.00 0.00 X 108199 0 10602 SUSAN HESS DIRECTOR 0.30 0.00 X 0 0 0 RICHARD RESSLER DIRECTOR 0.30 0.00 X 0 0 0 NANCY MARKS DIRECTOR 0.30 0.00 X 0 0 0 MICHAEL MILKEN DIRECTOR 0.30 15.00 X 0 0 0 MARY JO ROGERS DIRECTOR 0.30 0.00 X 0 0 0 MARIA BELL DIRECTOR 0.30 0.00 X 0 0 0 JONATHAN SOKOLOFF DIRECTOR 0.30 0.00 X 0 0 0 JONATHAN SIMONS DIRECTOR 0.30 0.00 X 0 0 0 JEFFREY ROWBOTTOM DIRECTOR 0.30 0.00 X 0 0 0 JASON FEDERICI DIRECTOR 0.30 0.00 X 0 0 0 JAMI GERTZ DIRECTOR 0.30 0.00 X 0 0 0 ELLIOTT SIGAL DIRECTOR 0.30 0.00 X 0 0 0 ELLEN DAVIS DIRECTOR 0.30 0.00 X 0 0 0 ELIZABETH STANTON DIRECTOR 0.30 0.00 X 0 0 0 DENISE KELLEN DIRECTOR 0.30 0.00 X 0 0 0 DAISY HELMAN DIRECTOR 0.30 0.00 X 0 0 0 BEN BLACK DIRECTOR 0.30 0.00 X 0 0 0 AMANDA ELLIAN DIRECTOR 0.30 0.00 X 0 0 0 SUZANNE TOPALIAN DIRECTOR 5.00 0.00 X 0 0 0 LEON BLACK DIRECTOR/CO-FOUNDER 0.30 0.00 X 0 0 0 DEBRA BLACK CHAIR/CO-FOUNDER 10.00 0.00 X X 0 0 0 MARGARET ANDERSON DIRECTOR/SECRETARY 0.50 0.00 X X 0 0 0 902460 1126783 158416 4 0 1 0 0 18953454 3384019 429623 22337473 324881 324881 870565 852073 18492 18492 18492 158950 18953454 359084 -200134 -200134 OTHER INCOME 990099 32061 32061 32061 22512773 0 0 175300 7529862 7529862 2627113 2627113 692387 429571 101533 161283 715587 443964 104936 166687 23194 14390 3401 5403 60694 37656 8900 14138 88256 54756 12942 20558 69143 69143 18450 18450 55888 42300 10054 3534 18571 8556 7157 2858 78284 36648 29311 12325 80106 28035 48373 3698 164078 104058 21096 38924 384245 357234 7957 19054 253609 251109 2500 8677 3998 3344 1335 DUES & SUBSCRIPTIONS 15614 7194 6017 2403 STATE FILING FEES 13463 6203 5188 2072 RESEARCH MATERIALS 1793 826 691 276 132013 97005 2608 32400 13031027 12080478 461101 489448 5230737 3563146 14230225 15414533 13734662 19744931 51403 28089 0 0 0 0 4025738 4361515 0 80505 37272765 43192719 65314 139414 17294177 12248645 280000 285000 109159 137174 17748650 12810233 X 5789453 17045668 13734662 13336818 19524115 30382486 37272765 43192719 X 9481746 495166 881459 X 0 1 X 1 0 X X X 1 THE MILKEN INSTITUTE 954240775 7 1 12080478 0 1 12080478 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0 PART IV, SECTION A, LINE 6: THE AMOUNT OF SUPPORT REPORTED TO MILKEN INSTITUTE REPRESENTS ALL PROGRAMMATIC EXPENDITURES MADE TOWARDS ENDING SUFFERING AND DEATH DUE TO MELANOMA INCLUDING ISSUED GRANTS, TECHNICAL MANAGEMENT OF GRANTS PROGRAM AND PATIENT ENGAGEMENT. ALL OF THESE EXPENDITURES ADVANCE THE MISSION OF BOTH MRA AND THE MILKEN INSTITUTE. MRA PROVIDES DIRECT SUPPORT TO PUBLIC CHARITIES AND EDUCATIONAL INSTITUTIONS FOR THE PURPOSES OF CANCER RESEARCH SPECIFICALLY RELATED TO MELANOMA. SUPPORTING THESE UNRELATED RESEARCH ORGANIZATIONS DIRECTLY SUPPORTS THE MISSION OF THE MILKEN INSTITUTE SINCE PART OF THE INSTITUTE'S MISSION IS TO IMPROVE HEALTH WORLDWIDE. MRA ALSO PROVIDES PATIENT ENGAGEMENT AND EDUCATION REATED TO MELANOMA TO IMPROVE AWARENESS OF MELANOMA AND ENGAGEMENT OF PATIENTS IN MELANOMA CLINICAL TRIALS. BY MRA PROVIDING THE GRANTS DIRECTLY TO THE CHARITIES AND EDUCATIONAL INSTITUTIONS, AND THROUGH PATIENT EDUCATION ACTIVITIES, MRA FURTHER ASSISTS THE MILKEN INSTITUTE. BECAUSE THERE IS A DIRECT LINE OF COMMUNICATION BETWEEN DONOR AND GRANT RECIPIENT, THE INSTITUTE CAN RELY ON MRA TO PROVIDE GRANT MONITORING AND GRANT SUPPORT SERVICES TO GRANT RECIPIENTS. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 2000 2000 12881160 12883160 794158 198540 0 0 1000000 705026 954200 794158 3453384 5180076 1500 2000 2000 2000 7500 250000 176257 238550 198540 863347 1295021 0 DUE TO AFFILIATE 137174 137174 X 23057501 495166 78522 -10510 563178 22494323 18450 18450 22512773 12199130 78522 -891969 -813447 13012577 18450 18450 13031027 PART X, LINE 2: IN ACCORDANCE WITH THE FINANCIAL ACCOUNTING STANDARDS BOARD'S (FASB'S) ACCOUNTING STANDARDS CODIFICATION TOPIC NO. 740, UNCERTAINTY IN INCOME TAXES, MRA RECOGNIZES THE IMPACT OF TAX POSITIONS IN THE FINANCIAL STATEMENTS IF THAT POSITION IS MORE LIKELY THAN NOT TO BE SUSTAINED ON AUDIT, BASED ON THE TECHNICAL MERITS OF THE POSITION. DURING THE YEAR ENDED DECEMBER 31, 2019, MRA PERFORMED AN EVALUATION OF UNCERTAIN TAX POSITIONS AND DID NOT NOTE ANY MATTERS THAT WOULD REQUIRE RECOGNITION IN THE FINANCIAL STATEMENTS OR WHICH MIGHT HAVE AN EFFECT ON ITS TAX-EXEMPT STATUS. PART XI, LINE 2D - OTHER ADJUSTMENTS: LOSS ON WRITE-OFF OF UNCOLLECTIBLE PLEDGES RECEIVABLE -10,510. PART XII, LINE 2D - OTHER ADJUSTMENTS: DISCOUNT ON GRANTS -204,449. GRANT FUNDS RETURNED -687,520. PART X, LINE 2 IN ACCORDANCE WITH THE FINANCIAL ACCOUNTING STANDARDS BOARD'S (FASB'S) ACCOUNTING STANDARDS CODIFICATION TOPIC NO. 740, UNCERTAINTY IN INCOME TAXES, MRA RECOGNIZES THE IMPACT OF TAX POSITIONS IN THE FINANCIAL STATEMENTS IF THAT POSITION IS MORE LIKELY THAN NOT TO BE SUSTAINED ON AUDIT, BASED ON THE TECHNICAL MERITS OF THE POSITION. DURING THE YEAR ENDED DECEMBER 31, 2019, MRA PERFORMED AN EVALUATION OF UNCERTAIN TAX POSITIONS AND DID NOT NOTE ANY MATTERS THAT WOULD REQUIRE RECOGNITION IN THE FINANCIAL STATEMENTS OR WHICH MIGHT HAVE AN EFFECT ON ITS TAX-EXEMPT STATUS. 1 EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION 373805 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION 1065889 MIDDLE EAST AND NORTH AFRICA - ALGERIA, BAHRAIN, DJIBOUTI, EGYPT, 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION 1187419 0 0 0 0 0 0 2627113 0 2627113 MIDDLE EAST AND NORTH AFRICA - ALGERIA, BAHRAIN, DJIBOUTI, EGYPT, - ALGERIA ESTABLISHED INVESTIGATOR AWARD, YOUNG INVESTIGATOR AWARD AND ONE COLLABORATIVE YOUNG INVESTIGATOR AWARD 712500 WIRE MIDDLE EAST AND NORTH AFRICA - ALGERIA, BAHRAIN, DJIBOUTI, EGYPT, - ALGERIA ESTABLISHED INVESTIGATOR AWARD 374919 WIRE MIDDLE EAST AND NORTH AFRICA - ALGERIA, BAHRAIN, DJIBOUTI, EGYPT, - ALGERIA PILOT AWARD 100000 WIRE EAST ASIA AND THE PACIFIC ESTABLISHED INVESTIGATOR AWARD 373805 WIRE EUROPE (INCLUDING ICELAND & GREENLAND) ESTABLISHED INVESTIGATOR AWARD 375000 WIRE EUROPE (INCLUDING ICELAND & GREENLAND) YOUNG INVESTIGATOR AWARD 219293 WIRE EUROPE (INCLUDING ICELAND & GREENLAND) ESTABLISHED INVESTIGATOR AWARD 247096 WIRE EUROPE (INCLUDING ICELAND & GREENLAND) YOUNG INVESTIGATOR AWARD 224500 WIRE 8 1 0 0 0 0 0 PART I, LINE 2: EACH PROPOSAL TO THE MRA IS REVIEWED FOR SCIENTIFIC MERIT AND TRANSLATIONAL AND CLINICAL IMPACT BY MRA'S WORLD-CLASS GRANT REVIEW COMMITTEE (GRC). CRITERIA ARE DESCRIBED IN THE MRA'S REQUEST FOR PROPOSALS. GRC MEMBERS ARE SENIOR THOUGHT-LEADERS IN MELANOMA AND CANCER RESEARCH. AFTER SCIENTIFIC PEER REVIEW BY THE GRC, THE MRA BOARD OF DIRECTORS APPROVES FINAL RESEARCH AWARDS FOR FUNDING. RESEARCH AWARD FUNDS ARE DISPENSED ON AN ANNUAL BASIS, CONTINGENT UPON MRA STAFF REVIEW OF ANNUAL PROGRESS REPORTS SUBMITTED BY THE GRANTEES. PART I, LINE 3: AWARDEES PROVIDE MRA WITH ANNUAL WRITTEN REPORTS OF THEIR RESEARCH PROGRESS AND COMPLIANCE WITH BUDGET GUIDELINES. FUNDS ARE DISTRIBUTED IN ANNUAL INSTALLMENTS AND NEXT YEAR'S INSTALLMENT IS NOT PROVIDED UNTIL SATISFACTORY REVIEW BY THE MRA CHIEF SCIENCE OFFICER AND SCIENTIFIC PROGRAM DIRECTOR. AWARDEES MUST KEEP SYSTEMATIC AND COMPLETE RECORDS ON THE RECEIPT AND DISBURSEMENT OF ALL AWARD FUNDS, AND MAY NOT COMMINGLE ANY FUNDS FROM OTHER SOURCES. PART III ACCOUNTING METHOD: PART IV, LINE 1 FORM 926 IS NOT REQUIRED TO BE FILED BECAUSE THE TRANSFER TO A FOREIGN CORPORATION DOES NOT MEET THE REQPORTING REQUIREMENTS IN IRC SEC. 6038(A)(1)(A). LEVERAGED FINANCE FIGHTS MELANOMA 2519257 2419557 99700 48690 98710 13900 17667 SOTHEBY'S BIENNIAL GALA 16593147 16533897 59250 49107 71025 15787 44198 19112404 18953454 158950 97797 169735 29687 61865 359084 -200134 1 MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02114 042697983 501(C)(3) 975000 1 YOUNG INVESTIGATOR AWARD, 2 ESTABLISHED INVESTIGATOR AWARDS NEW YORK UNIVERSITY SCHOOL OF MEDICINE 550 FIRST AVENUE NEW YORK NY 10016 135562308 PUBLIC UNIVERSITY 920000 2 DERMATOLOGY FELLOWS AWARDS, 1 ESTABLISHED INVESTIGATOR AWARD, 1 TEAM SCIENCE A THE REGENTS OF THE UNIVERSITY OF CALIFORNIA LOS ANGELES 10889 WILSHIRE BOULEVARD SUITE 700 LOS ANGELES CA 900951406 956006143 PUBLIC UNIVERSITY 910000 1 DERMATOLOGY FELLOWS AWARD, 1 TEAM SCIENCE AWARD, 1 ESTABLISHED INVESTIGATOR AW THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER 1515 HOLCOMBE BOULEVARD HOUSTON TX 770307009 746001118 PUBLIC UNIVERSITY 725000 1 YOUNG INVESTIGATOR AWARD, 1 TEAM SCIENCE AWARD MEMORIAL SLOAN KETTERING CANCER CENTER 1275 YORK AVENUE NEW YORK NY 100656007 131924236 501(C)(3) 670000 2 DERMATOLOGY FELLOWS AWARDS, 1 ESTABLISHED INVESTIGATOR AWARD, 1 YOUNG INVESTIG TRUSTEES OF BOSTON UNIVERSITY 881 COMMONWEALTH AVENUE BOSTON MA 22150 042103547 PUBLIC UNIVERSITY 375000 1 ESTABLISHED INVESTIGATOR AWARD HARVARD UNIVERSITY 1033 MASSACHUSETTS AVE 2ND FLOOR CAMBRIDGE MA 02138 042103580 PUBLIC UNIVERSITY 375000 1 ESTABLISHED INVESTIGATOR AWARD ST LOUIS UNIVERSITY 3545 LINDELL BLVD 3RD FLOOR SAINT LOUIS MO 63103 430654872 PUBLIC UNIVERSITY 375000 1 ESTABLISHED INVESTIGATOR AWARD WAYNE STATE UNIVERSITY 5057 WOODWARD AVENUE 13TH FLOOR DETROIT MI 48202 386028429 PUBLIC UNIVERSITY 374862 1 ESTABLISHED INVESTIGATOR AWARD WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVE NEW YORK NY 10065 131623978 PUBLIC UNIVERSITY 260000 1 DERMATOLOGY FELLOWS AWARD, YOUNG INVESTIGATOR AWARD MASSACHUSETTS INSTITUTE OF TECHNOLOGY 77 MASSACHUSETTS AVENUE CAMBRIDGE MA 02139 042103594 501(C)(3) 225000 1 YOUNG INVESTIGATOR AWARD THE ROCKEFELLER UNIVERSITY 1230 YORK AVENUE NEW YORK NY 10065 131624158 PUBLIC UNIVERSITY 225000 1 YOUNG INVESTIGATOR AWARD THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD MC 9029 DALLAS TX 753909029 756002868 PUBLIC UNIVERSITY 225000 1 YOUNG INVESTIGATOR AWARD WASHINTON UNIVERSITY 700 ROSEDALE AVE CD 1034 ST LOUIS MO 63112 430653611 PUBLIC UNIVERSITY 225000 1 YOUNG INVESTIGATOR AWARD THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 615 WEST 131ST STREET 3RD FL NEW YORK NY 10027 135598093 PUBLIC UNIVERSITY 125000 1 ESTABLISHED INVESTIGATOR AWARD THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO 1855 FOLSOM STREET BOX 0812 SAN FRANCISCO CA 94143 946036493 PUBLIC UNIVERSITY 125000 1 ESTABLISHED INVESTIGATOR AWARD BOSTON CHILDREN'S HOSPITAL 300 LONGWOOD AVENUE BOSTON MA 02115 042774441 501(C)(3) 100000 1 PILOT AWARD THE REGENTS OF THE UNIVERSITY OF CALIFORNIA BERKELEY 2195 HEARST AVENUE ROOM 159 BERKELEY CA 947201101 946002123 PUBLIC UNIVERSITY 100000 1 PILOT AWARD THE RECTOR AND VISITORS OF THE UNIVERSITY OF VIRGINIA SPONSORED PROGRAMS 1001 NORTH EMMET STREET CHARLOTTESVILLE VA 229044195 546001796 PUBLIC UNIVERSITY 100000 1 PILOT AWARD ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE NEW YORK NY 100296574 136171197 501(C)(3) 50000 1 PILOT AWARD MAYO CLINIC 200 FIRST STREET SW ROCHESTER MN 55905 416011702 501(C)(3) 35000 1 DERMATOLOGY FELLOWS AWARD YALE UNIVERSITY 2 WHITNEY AVENUE 6TH FLOOR NEW HAVEN CT 06510 060646973 PUBLIC UNIVERSITY 35000 1 DERMATOLOGY FELLOWS AWARD 22 PART I, LINE 2: EACH PROPOSAL TO THE MRA IS REVIEWED FOR SCIENTIFIC MERIT AND TRANSLATIONAL AND CLINICAL IMPACT BY MRA'S WORLD-CLASS GRANT REVIEW COMMITTEE (GRC). CRITERIA ARE DESCRIBED IN THE MRA'S REQUEST FOR PROPOSALS. GRC MEMBERS ARE SENIOR THOUGHT-LEADERS IN MELANOMA AND CANCER RESEARCH. AFTER SCIENTIFIC PEER REVIEW BY THE GRC, THE MRA BOARD OF DIRECTORS APPROVES FINAL RESEARCH AWARDS FOR FUNDING. RESEARCH AWARD FUNDS ARE DISPENSED ON AN ANNUAL BASIS, CONTINGENT UPON MRA STAFF REVIEW OF ANNUAL PROGRESS REPORTS SUBMITTED BY THE GRANTEES. ALL MRA-FUNDED INVESTIGATORS AND THEIR INSTITUTIONS MUST AGREE TO PERFORM THE RESEARCH PROPOSAL IN FULL COMPLIANCE WITH ALL APPLICABLE LAWS AND REGULATIONS, THE TERMS AND CONDITIONS OF THE MRA REQUEST FOR PROPOSALS, THE REQUIREMENTS OF THE MRA TERMS AND CONDITIONS OF THE RESEARCH PROPOSAL. AT ANY TIME DURING THE AWARD PERIOD, AWARDEES MUST NOTIFY AND MRA MUST APPROVE ANY SIGNIFICANT CHANGES TO THE RESEARCH PROPOSAL INCLUDING RESEARCH PLAN, BUDGET, AND PERSONNEL. AWARDEES PROVIDE MRA WITH ANNUAL WRITTEN REPORTS OF THEIR RESEARCH PROGRESS AND COMPLIANCE WITH BUDGET GUIDELINES. FUNDS ARE DISTRIBUTED IN ANNUAL INSTALLMENTS AND NEXT YEAR'S INSTALLMENT IS NOT PROVIDED UNTIL SATISFACTORY REVIEW BY THE MRA CHIEF SCIENCE OFFICER AND SCIENTIFIC PROGRAM DIRECTOR. AWARDEES MUST KEEP SYSTEMATIC AND COMPLETE RECORDS ON THE RECEIPT AND DISBURSEMENT OF ALL AWARD FUNDS, AND MAY NOT CO-MINGLE ANY FUNDS FROM OTHER SOURCES. X X X 0 0 0 0 0 0 0 1 0 MICHAEL KLOWDEN DIRECTOR 0 547272 0 200000 0 0 0 11200 0 29031 0 787503 0 0 JOHN HUNTER TREASURER 0 329511 0 50000 0 0 0 11200 0 39856 0 430567 0 0 MICHAEL KAPLAN PRESIDENT & CEO 324030 0 20000 0 0 0 11200 0 15564 0 370794 0 0 0 MARC HURLBERT CHIEF SCIENCE OFFICER 298529 0 0 0 0 0 7500 0 15564 0 321593 0 0 0 KRISTEN MUELLER SCIENTIFIC PROGRAM DIRECTOR 151702 0 0 0 0 0 6068 0 631 0 158401 0 0 0 PART I, LINE 7 EMPLOYEES WERE ELIGIBLE TO RECEIVE PERFORMANCE-BASED BONUSES. X 1 300000 FAIR MARKET VALUE X 3 108466 FAIR MARKET VALUE X GIFT BAGS 1 8000 FAIR MARKET VALUE X FOOD & BEVERAGE FOR EVENT 1 6657 FAIR MARKET VALUE X POSTER BOARDS AND SIGNS 1 6500 FAIR MARKET VALUE 0 1 0 PART I, COLUMN (B): NONCASH DONATIONS ARE LISTED BY TOTAL NUMBER OF DONORS. FORM 990, PART III, LINE 2 THE MRA STARTED A PATIENT ENGAGEMENT PROGRAM DURING THE YEAR. PLEASE REFER TO THE PROGRAM DESCRIPTION UNDER PART III, LINE 4B. FORM 990, PART V, LINE 2A THE ORGANIZATION DOES NOT ISSUE ANY W-2S FOR THEIR EMPLOYEES. THE SUPPORTED ORGANIZATION, THE MILKEN INSTITUTE, ISSUES ALL W-2S BUT EMPLOYEE COMPENSATION IS PAID BY THE MELANOMA RESEARCH ALLIANCE ITSELF. W-2S REPORTED ARE THOSE THAT ARE ISSUED BY MILKEN INSTITUTE ON BEHALF OF MRA. FORM 990, PART VI, SECTION A, LINE 2 DEBRA BLACK, LEON BLACK AND BEN BLACK HAVE A FAMILY RELATIONSHIP. DEBRA BLACK AND RICHARD RESSLER HAVE A FAMILY RELATIONSHIP. JAMI GERTZ AND DEBRA BLACK HAVE A FAMILY RELATIONSHIP. FORM 990, PART VI, SECTION A, LINE 8B THERE IS NO EXECUTIVE COMMITTEE DURING THE YEAR. FORM 990, PART VI, SECTION B, LINE 11B MRA'S CEO AND TREASURER REVIEW THE FORM 990. THE FINAL DRAFT IS DISTRIBUTED ELECTRONICALLY TO ALL THE BOARD MEMBERS BEFORE THE CEO SIGNS THE DOCUMENT AND IT IS FILED WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C AS STATED IN THE MRA BYLAWS, EACH DIRECTOR, TRUSTEE, PRINCIPAL OFFICER, AND MEMBER OF A COMMITTEE OF THE BOARD IS TO SIGN A STATEMENT ANNUALLY AFFIRMING THEY HAVE RECEIVED THE CONFLICT OF INTEREST POLICY, THEY HAVE READ AND UNDERSTAND IT, AND THEY AGREE TO COMPLY WITH IT. UPON POTENTIAL CONFLICT OF INTERESTS, THE BOARD OR COMMITTEE WILL RESOLVE THE CONFLICT IN THE BEST INTEREST OF THE ORGANIZATION. FORM 990, PART VI, SECTION B, LINE 15 ACCORDING TO THE MRA BYLAWS, MEMBERS OF THE BOARD REVIEW AND APPROVE THE MRA CEO AND KEY EMPLOYEES SALARY TO ENSURE IT IS JUST AND REASONABLE. DURING THIS ANNUAL REVIEW, MEMBERS OF THE BOARD USE THE FEDERAL FORM 990 OF OTHER ORGANIZATIONS FOR COMPARABLES. FORM 990, PART VI, SECTION C, LINE 19 MRA MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS AVAILABLE UPON REQUEST. A COPY OF FORM 990 AND THE AUDITED FINANCIAL STATEMENTS ARE POSTED TO THE ORGANIZATION'S WEBSITE. FORM 990, PART XI, LINE 9: LOSS ON WRITE-OFF OF UNCOLLECTIBLE PLEDGES RECEIVABLE -10,510. DISCOUNT ON GRANTS 204,449. GRANT FUNDS RETURNED 687,520. MILKEN INSTITUTE 1250 FOURTH STREET SANTA MONICA CA 90401 954240775 EDUCATIONAL, ECONOMIC RESEARCH, HEALTHCARE RESEARCH CA 501(C)(3) LINE 7 N/A 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 1 0 0 0